Teleflex Competitors

Teleflex (NYSE:TFX) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Dividends

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.4%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.3%. Teleflex pays out 12.2% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teleflex has raised its dividend for 1 consecutive years and Abbott Laboratories has raised its dividend for 48 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

91.3% of Teleflex shares are held by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are held by institutional investors. 2.2% of Teleflex shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Teleflex and Abbott Laboratories, as reported by MarketBeat.

Teleflex currently has a consensus target price of $384.6364, suggesting a potential upside of 3.08%. Abbott Laboratories has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Given Abbott Laboratories' higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Teleflex.

Profitability

This table compares Teleflex and Abbott Laboratories' net margins, return on equity and return on assets.

Volatility and Risk

Teleflex has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Valuation & Earnings

This table compares Teleflex and Abbott Laboratories' gross revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Teleflex (NYSE:TFX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Risk & Volatility

Teleflex has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Insider and Institutional Ownership

91.3% of Teleflex shares are owned by institutional investors. Comparatively, 79.9% of Medtronic shares are owned by institutional investors. 2.2% of Teleflex shares are owned by company insiders. Comparatively, 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Teleflex and Medtronic's revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Teleflex. Medtronic is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Dividends

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.4%. Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. Teleflex pays out 12.2% of its earnings in the form of a dividend. Medtronic pays out 50.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teleflex has increased its dividend for 1 consecutive years and Medtronic has increased its dividend for 43 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Teleflex and Medtronic's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Teleflex and Medtronic, as reported by MarketBeat.com.

Teleflex currently has a consensus target price of $384.6364, suggesting a potential upside of 3.08%. Medtronic has a consensus target price of $118.1538, suggesting a potential upside of 6.47%. Given Medtronic's higher possible upside, analysts clearly believe Medtronic is more favorable than Teleflex.

Summary

Teleflex beats Medtronic on 11 of the 17 factors compared between the two stocks.

Stryker (NYSE:SYK) and Teleflex (NYSE:TFX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Risk & Volatility

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Stryker and Teleflex, as provided by MarketBeat.

Stryker currently has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Teleflex has a consensus price target of $384.6364, suggesting a potential upside of 3.08%. Given Teleflex's stronger consensus rating and higher probable upside, analysts plainly believe Teleflex is more favorable than Stryker.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.0%. Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.4%. Stryker pays out 27.8% of its earnings in the form of a dividend. Teleflex pays out 12.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 1 consecutive years and Teleflex has raised its dividend for 1 consecutive years.

Earnings & Valuation

This table compares Stryker and Teleflex's revenue, earnings per share and valuation.

Stryker has higher revenue and earnings than Teleflex. Stryker is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 91.3% of Teleflex shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 2.2% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Stryker and Teleflex's net margins, return on equity and return on assets.

Teleflex (NYSE:TFX) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Teleflex has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Teleflex and Intuitive Surgical, as provided by MarketBeat.com.

Teleflex presently has a consensus price target of $384.6364, suggesting a potential upside of 3.08%. Intuitive Surgical has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Given Teleflex's stronger consensus rating and higher probable upside, analysts plainly believe Teleflex is more favorable than Intuitive Surgical.

Valuation and Earnings

This table compares Teleflex and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

91.3% of Teleflex shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 2.2% of Teleflex shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Teleflex and Intuitive Surgical's net margins, return on equity and return on assets.

Summary

Teleflex beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.

Teleflex (NYSE:TFX) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Volatility & Risk

Teleflex has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Teleflex and Becton, Dickinson and, as provided by MarketBeat.com.

Teleflex presently has a consensus price target of $384.6364, suggesting a potential upside of 3.08%. Becton, Dickinson and has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than Teleflex.

Dividends

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.4%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. Teleflex pays out 12.2% of its earnings in the form of a dividend. Becton, Dickinson and pays out 31.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teleflex has increased its dividend for 1 consecutive years and Becton, Dickinson and has increased its dividend for 49 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation and Earnings

This table compares Teleflex and Becton, Dickinson and's top-line revenue, earnings per share and valuation.

Becton, Dickinson and has higher revenue and earnings than Teleflex. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

91.3% of Teleflex shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 2.2% of Teleflex shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Teleflex and Becton, Dickinson and's net margins, return on equity and return on assets.

Summary

Teleflex beats Becton, Dickinson and on 11 of the 17 factors compared between the two stocks.

Teleflex (NYSE:TFX) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Teleflex has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Teleflex and Edwards Lifesciences, as provided by MarketBeat.com.

Teleflex presently has a consensus price target of $384.6364, suggesting a potential upside of 3.08%. Edwards Lifesciences has a consensus price target of $87.7222, suggesting a potential upside of 3.57%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Teleflex.

Valuation and Earnings

This table compares Teleflex and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Edwards Lifesciences has higher revenue and earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

91.3% of Teleflex shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 2.2% of Teleflex shares are owned by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Teleflex and Edwards Lifesciences' net margins, return on equity and return on assets.

Summary

Edwards Lifesciences beats Teleflex on 8 of the 15 factors compared between the two stocks.